These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 1717717)

  • 61. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
    J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
    Moore JP; Cao Y; Ho DD; Koup RA
    J Virol; 1994 Aug; 68(8):5142-55. PubMed ID: 8035514
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    Cao J; Sullivan N; Desjardin E; Parolin C; Robinson J; Wyatt R; Sodroski J
    J Virol; 1997 Dec; 71(12):9808-12. PubMed ID: 9371651
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    Earl PL; Broder CC; Long D; Lee SA; Peterson J; Chakrabarti S; Doms RW; Moss B
    J Virol; 1994 May; 68(5):3015-26. PubMed ID: 7512157
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
    Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
    Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Influence of deletions in N or C terminus of HIV-1 glycoprotein 120 on binding of infectivity-enhancing antibody.
    Lee CN; Robinson J; Cheng YL; Essex M; Lee TH
    AIDS Res Hum Retroviruses; 1994 Sep; 10(9):1065-9. PubMed ID: 7530023
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
    Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K
    J Virol; 1995 Jun; 69(6):3333-40. PubMed ID: 7538171
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
    Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
    Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins.
    Sugiura W; Broder CC; Moss B; Earl PL
    Virology; 1999 Feb; 254(2):257-67. PubMed ID: 9986792
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1).
    Neurath AR; Strick N
    Mol Immunol; 1990 Jun; 27(6):539-49. PubMed ID: 1696353
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
    J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.
    Dowbenko D; Nakamura G; Fennie C; Shimasaki C; Riddle L; Harris R; Gregory T; Lasky L
    J Virol; 1988 Dec; 62(12):4703-11. PubMed ID: 2460639
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide.
    Durda PJ; Bacheler L; Clapham P; Jenoski AM; Leece B; Matthews TJ; McKnight A; Pomerantz R; Rayner M; Weinhold KJ
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1115-23. PubMed ID: 1702301
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120.
    Takeda A; Robinson JE; Ho DD; Debouck C; Haigwood NL; Ennis FA
    J Clin Invest; 1992 Jun; 89(6):1952-7. PubMed ID: 1376330
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    Fung MS; Sun CR; Gordon WL; Liou RS; Chang TW; Sun WN; Daar ES; Ho DD
    J Virol; 1992 Feb; 66(2):848-56. PubMed ID: 1370558
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.
    Luallen RJ; Lin J; Fu H; Cai KK; Agrawal C; Mboudjeka I; Lee FH; Montefiori D; Smith DF; Doms RW; Geng Y
    J Virol; 2008 Jul; 82(13):6447-57. PubMed ID: 18434410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.